Angiotensin II human (Angiotensin II) is a vasoconstrictor that mainly acts on the AT1 receptor. Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis.
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | ANGIOTENSIN II;4474-91-3;Angiotensin II human;Hypertensin;Human angiotensin II;Angiotensin II (human);Ang II;5-L-Isoleucineangiotensin II;Angiotensin II, human;5-Isoleucine-angiotensin II;Angiotensin II (mouse);Giapreza;Asp-Arg-Val-Tyr-Ile-His-Pro-Phe;1-8-Angiotensin I;Ile(5)-angiotensin II;Isoleucine5-angiotensin II;CHEBI:2719;Delivert;angiotensine II;ANG-(1-8)Octapeptide;isoleucine(5)-angiotensin II;UNII-M089EFU921;DRVYIHPF;Ile5-angiotensin II;Angiotensin II, 5-L-isoleucine-;1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide;Angiotensin II (human type);CHEMBL408403;LJPC-501;Angiotensinum II;Angiotensin II acetate salt;L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine;L-Phenylalanine, N-(1-(N-(N-(N-(N-(N2-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-;N-(1-(N-(N-(N-(N-(N(2)-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine;(2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-5-yl)methyl)-17-amino-5-((S)-sec-butyl)-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-((diaminomethylene)amino)propyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid;(3S)-3-AMINO-3-{[(1S)-4-CARBAMIMIDAMIDO-1-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-CARBOXY-2-PHENYLETHYL]CARBAMOYL}PYRROLIDIN-1-YL]-3-(1H-IMIDAZOL-4-YL)-1-OXOPROPAN-2-YL]CARBAMOYL}-2-METHYLBUTYL]CARBAMOYL}-2-(4-HYDROXYPHENYL)ETHYL]CARBAMOYL}-2-METHYLPROPYL]CARBAMOYL}BUTYL]CARBAMOYL}PROPANOIC ACID;Alanine, N-(1-(N-(N-(N-(N-(N2-L-alpha-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-3-phenyl-, L-;Angiotensinum II (INN-Latin);Angiotensin cento, human;Angiotensina II (INN-Spanish);Angiotensin II, ile(5)-;Angiotensin ii [INN:JAN];Angiotensin 2;Angiotensin-(1-8) Octapeptide;Delivert (TN);C50H71N13O12;Angiotensin II heavy;Angiotensin II (9CI);Angiotensin II (USAN);ANGIOTENSIN II,HUMAN;SCHEMBL1189;Angiotensin II (acetate);Ang II (acetate);DRVYIHPF (acetate);GTPL2504;SCHEMBL9013957;DTXSID4036778;SCHEMBL20502357;CHEBI:48432;C01CX09;DTXSID30196288;CHEBI:131170;ty-10721;M089EFU921;Angiotensin II (human type) (JAN);BDBM50228195;BDBM50236697;HB3488;AKOS016010178;DB11842;FA73187;NCGC00167130-01;DA-70862;HY-13948;NS00074073;Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8;C02135;C75211;D02014;DRVY-I*-HPF [I*= I(13C6,15N)];EN300-19742056;Q412999;32044-01-2, 4474-91-3 (salt);ANG-(1-8)Octapeptide, Hypertensin, 4474-91-3, Giapreza;Conalbumin (328-332), 1226776-54-0, RVPSL peptide;ProteoMass(TM) Angiotensin II MALDI-MS Standard, vial of 10 nmol;(2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-4-yl)methyl)-17-amino-5-((S)-sec-butyl)-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid;(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(2S)-1-[(2S)-2-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl}-2-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-4-[(diaminomethylidene)amino]butyl]carbamoyl}propanoic acid;L-phenylalanine, L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-; |
M.F/Formula | C50H71N13O12 |
M.W/Mr. | 1046.2 |
Sequence | One Letter Code:DRVYIHPF Three Letter Code:H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH |
Source# | Synthetic |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1 |
InChI Key | CZGUSIXMZVURDU-JZXHSEFVSA-N |
1. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com